Cargando…

In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS)

Postzygotic mutations of the PIK3CA [phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha] gene constitutively activate the PI3K/AKT/mTOR pathway in PIK3CA-related overgrowth spectrum (PROS) patients, causing congenital mosaic tissue overgrowth that even multiple surgeries cannot s...

Descripción completa

Detalles Bibliográficos
Autores principales: Ranieri, C., Di Tommaso, S., Loconte, D. C., Grossi, V., Sanese, P., Bagnulo, R., Susca, F. C., Forte, G., Peserico, A., De Luisi, A., Bartuli, A., Selicorni, A., Melis, D., Lerone, M., Praticò, A. D., Abbadessa, G., Yu, Y., Schwartz, B., Ruggieri, Martino, Simone, Cristiano, Resta, Nicoletta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956072/
https://www.ncbi.nlm.nih.gov/pubmed/29549527
http://dx.doi.org/10.1007/s10048-018-0540-1
_version_ 1783323823603449856
author Ranieri, C.
Di Tommaso, S.
Loconte, D. C.
Grossi, V.
Sanese, P.
Bagnulo, R.
Susca, F. C.
Forte, G.
Peserico, A.
De Luisi, A.
Bartuli, A.
Selicorni, A.
Melis, D.
Lerone, M.
Praticò, A. D.
Abbadessa, G.
Yu, Y.
Schwartz, B.
Ruggieri, Martino
Simone, Cristiano
Resta, Nicoletta
author_facet Ranieri, C.
Di Tommaso, S.
Loconte, D. C.
Grossi, V.
Sanese, P.
Bagnulo, R.
Susca, F. C.
Forte, G.
Peserico, A.
De Luisi, A.
Bartuli, A.
Selicorni, A.
Melis, D.
Lerone, M.
Praticò, A. D.
Abbadessa, G.
Yu, Y.
Schwartz, B.
Ruggieri, Martino
Simone, Cristiano
Resta, Nicoletta
author_sort Ranieri, C.
collection PubMed
description Postzygotic mutations of the PIK3CA [phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha] gene constitutively activate the PI3K/AKT/mTOR pathway in PIK3CA-related overgrowth spectrum (PROS) patients, causing congenital mosaic tissue overgrowth that even multiple surgeries cannot solve. mTOR inhibitors are empirically tested and given for compassionate use in these patients. PROS patients could be ideal candidates for enrolment in trials with PI3K/AKT pathway inhibitors, considering the “clean” cellular setting in which a unique driver, a PIK3CA mutation, is present. We aimed to assess the effects of blocking the upstream pathway of mTOR on PROS patient-derived cells by using ARQ 092, a potent, selective, allosteric, and experimental orally bioavailable and highly selective AKT-inhibitor with activity and long-term tolerability, currently under clinical development for treatment of cancer and Proteus syndrome. Cell samples (i.e., primary fibroblasts) were derived from cultured tissues obtained from six PROS patients [3 boys, 3 girls; aged 2 to 17 years] whose spectrum of PIK3A-related overgrowth included HHML [hemihyperplasia multiple lipomatosis; n = 1], CLOVES [congenital lipomatosis, overgrowth, vascular malformations, epidermal nevi, spinal/skeletal anomalies, scoliosis; n = 1], and MCAP [megalencephaly capillary malformation syndrome; n = 4]. We performed the following: (a) a deep sequencing assay of PI3K/AKT pathway genes in the six PROS patients’ derived cells to identify the causative mutations and (b) a pathway analysis to assess the phosphorylation status of AKT [Ser473 and Thr308] and its downstream targets [pAKTS1 (Thr246), pRPS6 (Ser235/236), and pRPS6Kβ1 (Ser371)]. The anti-proliferative effect of ARQ 092 was tested and compared to other PI3K/AKT/mTOR inhibitors [i.e., wortmannin, LY249002, and rapamycin] in the six PROS patient-derived cells. Using ARQ 092 to target AKT, a critical node connecting PI3K and mTOR pathways, we observed the following: (1) strong anti-proliferative activity [ARQ 092 at 0.5, 1, and 2.5 μM blunted phosphorylation of AKT and its downstream targets (in the presence or absence of serum) and inhibited proliferation after 72 h; rapamycin at 100 nM did not decrease AKT phosphorylation] and (2) less cytotoxicity as compared to rapamycin and wortmannin. We demonstrated the following: (a) that PROS cells are dependent on AKT; (b) the advantage of inhibiting the pathway immediately downstream of PI3K to circumventing problems depending on multiple classes a PI3K kinases; and (c) that PROS patients benefit from inhibition of AKT rather than mTOR. Clinical development of ARQ 092 in PROS patients is on going in these patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10048-018-0540-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5956072
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-59560722018-05-18 In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS) Ranieri, C. Di Tommaso, S. Loconte, D. C. Grossi, V. Sanese, P. Bagnulo, R. Susca, F. C. Forte, G. Peserico, A. De Luisi, A. Bartuli, A. Selicorni, A. Melis, D. Lerone, M. Praticò, A. D. Abbadessa, G. Yu, Y. Schwartz, B. Ruggieri, Martino Simone, Cristiano Resta, Nicoletta Neurogenetics Original Article Postzygotic mutations of the PIK3CA [phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha] gene constitutively activate the PI3K/AKT/mTOR pathway in PIK3CA-related overgrowth spectrum (PROS) patients, causing congenital mosaic tissue overgrowth that even multiple surgeries cannot solve. mTOR inhibitors are empirically tested and given for compassionate use in these patients. PROS patients could be ideal candidates for enrolment in trials with PI3K/AKT pathway inhibitors, considering the “clean” cellular setting in which a unique driver, a PIK3CA mutation, is present. We aimed to assess the effects of blocking the upstream pathway of mTOR on PROS patient-derived cells by using ARQ 092, a potent, selective, allosteric, and experimental orally bioavailable and highly selective AKT-inhibitor with activity and long-term tolerability, currently under clinical development for treatment of cancer and Proteus syndrome. Cell samples (i.e., primary fibroblasts) were derived from cultured tissues obtained from six PROS patients [3 boys, 3 girls; aged 2 to 17 years] whose spectrum of PIK3A-related overgrowth included HHML [hemihyperplasia multiple lipomatosis; n = 1], CLOVES [congenital lipomatosis, overgrowth, vascular malformations, epidermal nevi, spinal/skeletal anomalies, scoliosis; n = 1], and MCAP [megalencephaly capillary malformation syndrome; n = 4]. We performed the following: (a) a deep sequencing assay of PI3K/AKT pathway genes in the six PROS patients’ derived cells to identify the causative mutations and (b) a pathway analysis to assess the phosphorylation status of AKT [Ser473 and Thr308] and its downstream targets [pAKTS1 (Thr246), pRPS6 (Ser235/236), and pRPS6Kβ1 (Ser371)]. The anti-proliferative effect of ARQ 092 was tested and compared to other PI3K/AKT/mTOR inhibitors [i.e., wortmannin, LY249002, and rapamycin] in the six PROS patient-derived cells. Using ARQ 092 to target AKT, a critical node connecting PI3K and mTOR pathways, we observed the following: (1) strong anti-proliferative activity [ARQ 092 at 0.5, 1, and 2.5 μM blunted phosphorylation of AKT and its downstream targets (in the presence or absence of serum) and inhibited proliferation after 72 h; rapamycin at 100 nM did not decrease AKT phosphorylation] and (2) less cytotoxicity as compared to rapamycin and wortmannin. We demonstrated the following: (a) that PROS cells are dependent on AKT; (b) the advantage of inhibiting the pathway immediately downstream of PI3K to circumventing problems depending on multiple classes a PI3K kinases; and (c) that PROS patients benefit from inhibition of AKT rather than mTOR. Clinical development of ARQ 092 in PROS patients is on going in these patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10048-018-0540-1) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2018-03-16 2018 /pmc/articles/PMC5956072/ /pubmed/29549527 http://dx.doi.org/10.1007/s10048-018-0540-1 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Ranieri, C.
Di Tommaso, S.
Loconte, D. C.
Grossi, V.
Sanese, P.
Bagnulo, R.
Susca, F. C.
Forte, G.
Peserico, A.
De Luisi, A.
Bartuli, A.
Selicorni, A.
Melis, D.
Lerone, M.
Praticò, A. D.
Abbadessa, G.
Yu, Y.
Schwartz, B.
Ruggieri, Martino
Simone, Cristiano
Resta, Nicoletta
In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS)
title In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS)
title_full In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS)
title_fullStr In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS)
title_full_unstemmed In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS)
title_short In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS)
title_sort in vitro efficacy of arq 092, an allosteric akt inhibitor, on primary fibroblast cells derived from patients with pik3ca-related overgrowth spectrum (pros)
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956072/
https://www.ncbi.nlm.nih.gov/pubmed/29549527
http://dx.doi.org/10.1007/s10048-018-0540-1
work_keys_str_mv AT ranieric invitroefficacyofarq092anallostericaktinhibitoronprimaryfibroblastcellsderivedfrompatientswithpik3carelatedovergrowthspectrumpros
AT ditommasos invitroefficacyofarq092anallostericaktinhibitoronprimaryfibroblastcellsderivedfrompatientswithpik3carelatedovergrowthspectrumpros
AT locontedc invitroefficacyofarq092anallostericaktinhibitoronprimaryfibroblastcellsderivedfrompatientswithpik3carelatedovergrowthspectrumpros
AT grossiv invitroefficacyofarq092anallostericaktinhibitoronprimaryfibroblastcellsderivedfrompatientswithpik3carelatedovergrowthspectrumpros
AT sanesep invitroefficacyofarq092anallostericaktinhibitoronprimaryfibroblastcellsderivedfrompatientswithpik3carelatedovergrowthspectrumpros
AT bagnulor invitroefficacyofarq092anallostericaktinhibitoronprimaryfibroblastcellsderivedfrompatientswithpik3carelatedovergrowthspectrumpros
AT suscafc invitroefficacyofarq092anallostericaktinhibitoronprimaryfibroblastcellsderivedfrompatientswithpik3carelatedovergrowthspectrumpros
AT forteg invitroefficacyofarq092anallostericaktinhibitoronprimaryfibroblastcellsderivedfrompatientswithpik3carelatedovergrowthspectrumpros
AT pesericoa invitroefficacyofarq092anallostericaktinhibitoronprimaryfibroblastcellsderivedfrompatientswithpik3carelatedovergrowthspectrumpros
AT deluisia invitroefficacyofarq092anallostericaktinhibitoronprimaryfibroblastcellsderivedfrompatientswithpik3carelatedovergrowthspectrumpros
AT bartulia invitroefficacyofarq092anallostericaktinhibitoronprimaryfibroblastcellsderivedfrompatientswithpik3carelatedovergrowthspectrumpros
AT selicornia invitroefficacyofarq092anallostericaktinhibitoronprimaryfibroblastcellsderivedfrompatientswithpik3carelatedovergrowthspectrumpros
AT melisd invitroefficacyofarq092anallostericaktinhibitoronprimaryfibroblastcellsderivedfrompatientswithpik3carelatedovergrowthspectrumpros
AT leronem invitroefficacyofarq092anallostericaktinhibitoronprimaryfibroblastcellsderivedfrompatientswithpik3carelatedovergrowthspectrumpros
AT praticoad invitroefficacyofarq092anallostericaktinhibitoronprimaryfibroblastcellsderivedfrompatientswithpik3carelatedovergrowthspectrumpros
AT abbadessag invitroefficacyofarq092anallostericaktinhibitoronprimaryfibroblastcellsderivedfrompatientswithpik3carelatedovergrowthspectrumpros
AT yuy invitroefficacyofarq092anallostericaktinhibitoronprimaryfibroblastcellsderivedfrompatientswithpik3carelatedovergrowthspectrumpros
AT schwartzb invitroefficacyofarq092anallostericaktinhibitoronprimaryfibroblastcellsderivedfrompatientswithpik3carelatedovergrowthspectrumpros
AT ruggierimartino invitroefficacyofarq092anallostericaktinhibitoronprimaryfibroblastcellsderivedfrompatientswithpik3carelatedovergrowthspectrumpros
AT simonecristiano invitroefficacyofarq092anallostericaktinhibitoronprimaryfibroblastcellsderivedfrompatientswithpik3carelatedovergrowthspectrumpros
AT restanicoletta invitroefficacyofarq092anallostericaktinhibitoronprimaryfibroblastcellsderivedfrompatientswithpik3carelatedovergrowthspectrumpros